Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...

Adrenergic Receptors: ɑ Subtype

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Biomarkers for Lung Nodule Risk Stratification: Are We There Yet?

Diagnostics (Basel, Switzerland)·2026

Same author

Synchronization of the 12-hour circatidal rhythm maintains the kidney through repeated cycles of warm reperfusion in the hibernating ground squirrel.

Function (Oxford, England)·2026

Same author

Carbapenem-resistant Enterobacterales across the UK: a nationwide study of carbapenemase testing and novel antimicrobial activity.

International journal of antimicrobial agents·2026

Same author

A novel face scale and National Early Warning Score 2 prediction model to assess deteriorating patients in hospital wards: A quick visual early warning score study.

Australian critical care : official journal of the Confederation of Australian Critical Care Nurses·2026

Same author

Rare detection of Hepatitis C virus genotype 4 in a patient with pulmonary tuberculosis: First report from central India.

Indian journal of medical microbiology·2026

Same author

Pd-Catalyzed Regioselective Arylation of <i>gem</i>-Difluoroallenes: Access to Tertiary and Quaternary Center-Tethered Difluoroalkenes.

Organic letters·2026

Search research articles

Related Experiment Video

Updated: Jul 7, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

An ab initio study of AT2 antagonists.

Swati Jain, Arpita Yadav

Chemical Biology & Drug Design

|February 6, 2008

Summary

This study used molecular modeling to analyze angiotensin II and AT2 antagonists, revealing how antagonists block receptors without activating them. Poor antagonists closely mimic angiotensin II's receptor interactions.

Area of Science:

Computational chemistry
Molecular modeling
Pharmacology

Background:

Angiotensin II (a natural hormone) activates AT1/AT2 receptors, causing vasoconstriction and hypertension.
AT2 antagonists are drugs designed to block these receptors.

Discussion:

This research employed ab initio molecular orbital calculations and molecular docking to model the AT2 receptor.
Ligand-receptor interactions between angiotensin II, AT2 antagonists, and the AT2 receptor model were systematically analyzed.
Calculated interaction energies were correlated with experimental biological potency data.

Key Insights:

AT2 antagonists possess sufficient interactions to block receptor activity but may not induce it.
Poor antagonists exhibit a high degree of similarity to angiotensin II in their receptor binding patterns.

More Related Videos

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development

Published on: January 26, 2018

Related Experiment Videos

Last Updated: Jul 7, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development

Published on: January 26, 2018

The study elucidates the mechanistic basis for AT2 antagonist efficacy.

Outlook:

Further computational and experimental studies can refine AT2 antagonist design.
Understanding these interactions may lead to novel therapeutic strategies for hypertension.
This work contributes to the mechanistic understanding of angiotensin II receptor modulation.